Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Awakn Life Sciences ( (TSE:AWKN) ) has issued an announcement.
Awakn Life Sciences Corp. has completed its sale to Solvonis Therapeutics plc, resulting in the acquisition of all outstanding shares and units by Solvonis. This transaction, approved by shareholders and the Supreme Court of British Columbia, will lead to the delisting of Awakn’s shares from the Canadian Securities Exchange and OTCPink Market. Solvonis, a clinical-stage biotechnology company, focuses on innovative treatments for addiction and mental health disorders, with a significant emphasis on Alcohol Use Disorder and PTSD, positioning itself as a key player in addressing high-burden neuropsychiatric conditions.
More about Awakn Life Sciences
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for addiction, particularly Alcohol Use Disorder, which affects millions globally. The company aims to commercialize its R&D pipeline to provide breakthrough solutions for addiction sufferers.
Technical Sentiment Signal: Sell
Current Market Cap: C$3.96M
For a thorough assessment of AWKN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue